Abstract:Objective To investigate the effect of pentoxifylline (PTX) on ethanol metabolic enzymes and peroxisome proliferator-activated receptor alpha (PPAR-α) in C57BL/6 mice with alcoholic liver disease. Meth-ods Sixty -four mice were randomly divided into alcoholic liver disease model, PTX intervention and control group; Acute alcoholic liver injury was induced in mice by intragastric administration with 50% alcohol,and chronic alcoholic liver injury was induced by intragastric administration with 20% alcohol daily for six weeks;Serum alcohol dehydrogenase (ADH) and cytochrome P4502E1 (CYP2E1) activity was measured by colorimetric method;The mRNA levels of ADH,CYP2E1 and PPAR-α were measured by PT-PCR;The protein expression of CYP2E1 and PPAR-α was determined by immunohistochemistry. Results The serum activity of ADH did not differ among mice with acute [(11.2±1.6)U/ml] or chronic [(5.8±1.4) U/ml] alcoholic liver injury and controls [(12.5±1.2)U/ml and(4.3±0.6)U/ml,respectively];In mice with acute and chronic liver injury,the CYP2E1 activ-ity was(12.2±1.8)U/ml and(11.8±1.7) U/ml,respectively,significantly higher than those in normal controls[(7.9±1.4) U/ml and (6.5±1.2) U/ml,P<0.01)] and those in PTX-intervented mice [(8.1±1.5) U/ml and (7.8±1.5)U/ml, P<0.01];The relative CYP2E1 positive cells in liver tissues in mice with acute and chronic alcoholic liver injury were (765±21) and (682±25),respectively,significantly higher than those in normal controls [(308±12) and (305±18),P<0.01)] and in mice with high-dosage of PTX intervention [(521±18) and (418±12),respectively,P<0.01];The mRNA levels of ADH in liver tissues of mice with acute and chronic alcoholic liver injury were simi-lar to that in the controls, however, the relative CYP2E1 mRNA levels[(1.47±0.32) and (1.13±0.52)] were sig-nificantly higher than those in normal controls [(0.89±0.23) and (0.45±0.28),respectively,P<0.01)] and in mice with high-dose of PTX[(0.92±0.27) and(0.48±0.32),respectively,P<0.01)];PPAR-α mRNA levels in liver tissues did not differ among mice with acute liver injury and normal controls,however,it was significantly lower than that in normal controls (0.85±0.21) in liver of mice with chronic alcoholic liver injury [(0.45±0.31),P<0.05];The PPAR-α positive cells in mice of acute and chronic alcohol injury were(322±15) and(262±23),respectively,sig-nificantly higher than those in normal controls [(721±18)and (689±14),P<0.01] and in mice with high-dose of PTX intervention[(548±20) and (725±19),P<0.01]. Conclusion PTX attenuates acute or chronic alcoholic liver injury,probably by through up-regulation of CYP2E1 and down-regulation of PPAR-α.

Effects of Pentoxifylline on Nonalcoholic Fatty Liver Disease: a Meta-Analysis.

Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies

Systematic Review on the Treatment of Pentoxifylline in Patients with Non-Alcoholic Fatty Liver Disease

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial

Fatty Acid and Non-Alcoholic Fatty Liver Disease: Meta-analyses of Case-Control and Randomized Controlled Trials.

Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis

Efficacy of Orlistat in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease.

Betaine Alleviates Nonalcoholic Fatty Liver Disease (NAFLD) Via a Manner Involving BHMT/FTO/m6A/ PGC1α Signaling.

Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease

Efficacy and Safety of Combining Pentoxifylline with Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Diabetic Nephropathy: a Meta-Analysis

The effects of fish oil plus vitamin D 3 intervention on non-alcoholic fatty liver disease: a randomized controlled trial

Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis

Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis- A randomized pilot study

The effect of omega-3 unsaturated fatty acids on non-alcoholic fatty liver disease: A systematic review and meta-analysis of RCTs

The effects of supplementation of probiotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials

Effects of pentoxifylline on ethanol metabolic enzymes and peroxisome proliferator-activated receptor alpha in mice with alcoholic liver disease

Evaluating the efficacy of pentoxifylline in the treatment of oral submucous fibrosis: a meta-analysis.

Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Evaluating the Efficacy of Pentoxifylline in the Treatment of Oral Submucous Fibrosis: A Meta‐analysis

Omega-3 Polyunsaturated Fatty Acids: A Specific Liver Drug for Non-Alcoholic Fatty Liver Disease (NAFLD)